Trinity Biotech (NASDAQ:TRIB) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of Trinity Biotech (NASDAQ:TRIB) from a hold rating to a sell rating in a research report report published on Thursday morning.

Trinity Biotech Stock Performance

Shares of TRIB opened at $0.68 on Thursday. Trinity Biotech has a 52 week low of $0.63 and a 52 week high of $3.55. The stock has a market capitalization of $12.28 million, a price-to-earnings ratio of -0.30 and a beta of 1.03. The stock has a fifty day moving average of $0.84 and a 200-day moving average of $1.25.

Institutional Trading of Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. Institutional investors and hedge funds own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.